AB Sciex

The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.

The year saw the launch of high-profile platforms as well as efforts by a number of parties to streamline mass spec technologies for the clinic.

The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.

Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.

Since introducing new clinical platforms last year, Sciex has launched an automated sample prep system while Thermo Fisher has begun customer beta testing.

In the last year, both Sciex and Thermo Fisher have launched clinical platforms, but whether they will prove commercial successes remains to be seen.

The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.

The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35. 

Factors like the country's interest in multiplexed dx panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said a Sciex official.

The venture with the Chinese diagnostics firm will focus on developing and commercializing tests and reagents for Scienx's 4500MD triple quad mass spec system.

Pages